Altimmune announces inducement grants under nasdaq listing rule 5635(c)(4)

Gaithersburg, md., dec. 13, 2021 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced that the compensation committee of its board of directors granted equity awards under altimmune's 2018 inducement grant plan, as a material inducement to employ richard eisenstadt as altimmune's chief financial officer effective december 31, 2021. the equity awards were approved on december 9, 2021, in accordance with nasdaq listing rule 5635(c)(4).
ALT Ratings Summary
ALT Quant Ranking